NCT06462014

Description of Relugolix Use in Patients With Prostate Cancer Within the VHA

Description of Relugolix Use in Patients With Prostate Cancer: An Analysis of National Veterans Affairs Health Care Network Data

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 507 (actual)
• Sponsor: Pfizer · Industry
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this real-world study is the learn about the demographics and clinical characteristics of patients with prostate cancer who initiated relugolix

Detailed description

Prostate cancer (PC) is the most common cancer and the second leading cause of cancer death among men in the United States. Androgen deprivation therapy (ADT) such as injectable luteinizing hormone-releasing hormone (LHRH) agonists (e.g., leuprolide) is the standard of care for PC patients. ADT treatment can suppress testosterone level to castrate level and delay the progression of the disease. Relugolix is a recently approved oral GnRH antagonist. While the introduction of relugolix has offered a unique opportunity for patients with PC, it's vital to understand how it is being used in real-world.

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
DRUG	Relugolix	relugolix

Timeline

• Start date: 2024-06-19
• Primary completion: 2024-12-13
• Completion: 2024-12-13
• First posted: 2024-06-17
• Last updated: 2025-12-11
• Results posted: 2025-12-11

Locations

1 site across 1 country: United States